ENDP up +1.27% percent Today $ENDP High is at 67.08 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
ENDP up +1.27% percent Today $ENDP High is at 67.08 and the Low 66.13 with current volume of 119,992.

Recent News posted below.

Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/

ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News

After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 66.72 (+0.46)

Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 66.72 (+0.46), ACT: 249.80 (+6.03), JAZZ: 171.30 (-3.27), UNH: 96.09 (+0.98), CELG: 104.54 (+0.49), CELGZ: 3.28 (unch)

La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 66.72 (+0.46), LCI: 47.45 (+0.57), BCRX: 10.17 (+0.10), LJPC: 11.29 (+0.23)

Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 66.72 (+0.46), ENL.TO: 74.77 (-0.38)

Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST

ENDP: 66.72 (+0.46), AUXL: 32.24 (+0.07)

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 66.72 (+0.46), RDY: 55.94 (-0.09)

Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 210.46 (+11.81), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), ABBV: 65.29 (+1.29)

Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST

ENDP: 66.71 (+0.45)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.45 (+0.55), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), SHPG: 204.81 (+2.19), DNDN: 0.16 (+0.05), SNSS: 2.50 (+0.83), ABBV: 65.29 (+1.29), SNY: 47.39 (+0.71), MNKD: 6.14 (-0.02), XOMA: 3.97 (+0.05)

Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 66.71 (+0.45)

Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST

ENDP: 66.71 (+0.45)

Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST

ENDP: 66.71 (+0.45)

Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST

ENDP: 66.71 (+0.45)

Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 66.71 (+0.45), ENL.TO: 74.77 (-0.38)

Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST

MDLZ: 38.20 (+0.04), CSTE: 59.51 (+0.14), FSS: 15.67 (+0.02), HL: 2.46 (-0.06), BBEP: 15.12 (-0.43), RRD: 16.90 (-0.03), CNP: 24.16 (+0.12), INXN: 28.26 (-0.02), OGE: 36.53 (+0.18), MNTA: 10.63 (unch), GLDD: 7.05 (-0.18), AXAS: 3.89 (-0.18), MEMP: 16.13 (-0.24), PWE: 4.16 (-0.06), ROC: 79.15 (-0.04), SSYS: 104.67 (-0.18), DNR: 9.93 (-1.27), MVIS: 1.70 (unch), PWR: 33.09 (-0.07), COV: 94.39 (+0.41), SMG: 59.94 (-0.66), SEP: 56.90 (+0.54), CLH: 49.80 (+0.85), ATHM: 42.88 (-1.70), STWD: 23.46 (-0.06), BPI: 10.96 (-0.30), LVLT: 48.73 (-0.31), AVA: 33.70 (+0.24), MGA: 104.19 (+0.27), BSFT: 27.42 (-0.08), EE: 37.89 (+0.34), CTSH: 53.03 (-0.25), DAVE: 25.69 (-0.06), NRG: 31.22 (-0.09), CEQP: 8.37 (-0.09), ACT: 249.80 (+6.03), AWR: 34.52 (+0.28), DUK: 80.05 (+0.94), LAMR: 52.77 (+0.22), CCC: 21.06 (-0.16), HFC: 43.18 (+0.35), RTI: 23.45 (-0.17), CHK: 23.03 (-0.18), NUS: 39.26 (-0.14), NICE: 46.40 (-0.02), HRC: 45.04 (+0.28), ENDP: 66.71 (+0.45), SE: 38.44 (+0.32), CBB: 3.41 (-0.06), GTN: 10.20 (+0.09), ANSS: 79.94 (+0.15), RLGY: 42.73 (-0.24), ENB: 45.26 (-0.11), SBGI: 27.96 (-0.13), ARIA: 6.05 (-0.10), LPX: 14.61 (unch), RDC: 23.43 (-0.32), KELYA: 15.12 (-0.30)

Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.88 (+0.74), ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), PFE: 30.01 (-0.33)

Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT

ENDP: 66.71 (+0.45)

3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), ACT: 249.80 (+6.03), AMGN: 158.68 (+1.00), TKMR: 17.09 (+0.68), GSK: 45.84 (+0.10), AGN: 210.48 (+11.83), JNJ: 108.31 (+0.15), SHPG: 204.81 (+2.19), MRK: 59.62 (+0.55), INFI: 14.25 (+0.15), ABBV: 65.29 (+1.29), KPTI: 40.49 (+0.72)

Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 66.71 (+0.45), PRGO: 154.09 (-0.37), AUXL: 32.24 (+0.07), DEPO: 15.23 (+0.23), AMPE: 3.32 (-0.02)

Endo International plc (ENDPQ) Stock Research Links

ENDPQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading